This article was originally published on TipRanks.com Shares of Acadia Pharmaceuticals Inc.
Shares of Acadia Pharmaceuticals plunged more than 15% in early trade on Monday after the biopharmaceutical company received a Complete Response Letter (CRL) …
Shares in Acadia Pharmaceuticals (ACAD) plunged 12% in Monday’s extended trading, after the company announced disappointing top-line results from its 298 patient Phase …
Acadia Pharmaceuticals Inc. (ACAD) has announced that it has filed a supplemental New Drug Application (sNDA) to the U.
After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …
J.P.
Acadia Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company based in San Diego and focused on the development of therapeutics to treat central nervous system …
Cowen’s Ritu Baral’s conversations with key experts in the field with Nuplazid experience leave her positive; albeit somewhat ‘cautious’ on the impact of ACAD’s controversy.
ACADIA Pharmaceuticals (NASDAQ:ACAD) just got hit with a bad bullet: a CNN research report questioning lead asset Nuplazid’s risk/reward as a treatment of …
Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?